Bionano Genomics Inc. Common Stock (BNGO)

FairStock Score: 55/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earning power, honest accounting, and a margin of safety. Bionano does not yet fit that mold. It sells genome analysis tools and software, but it has been unprofitable in each of the last four years. FairStock's Lynch category is none for exactly that reason. In fiscal 2025, the year ended 2025-12-31, revenue was $28.5M and net income was -$26.4M. In fiscal 2024, the year ended 2024-12-31, revenue was $30.8M and net income was -$112.0M. In fiscal 2023, the year ended 2023-12-31, revenue was $36.1M and net income was -$232.5M. So annual revenue has shrunk, while losses remain large. The latest quarter, fiscal Q2 2026 ended 2026-06-30, showed revenue of $8.2M and net income of -$7.4M, versus $6.7M revenue and -$6.9M net income in fiscal Q2 2025. That is some top-line improvement, but the company still lost more money. At the 2026-10-13 close of $1.36, FairStock calculates a P/B of 0.51, which looks cheap, but P/E is -0.45 and meaningless without profits. Free cash flow is -$20.5M trailing twelve months, a -127.9% FCF yield against a $16.0M market cap. Altman Z-score is -20.99, and ROE is -83.56%. A low debt-to-equity of 0.21 and Piotroski 5/9 are small comforts. Without a clear path to cash generation, the apparent asset discount is not a margin of safety; it is a hope. I would want evidence of durable revenue growth and sharply reduced cash burn before considering the business investment-grade.

In plain English: Bionano Genomics sells tools and software that help scientists study DNA. The business is growing sales in its latest quarter but still loses money and burns cash faster than its entire market value, so it looks financially weak. The stock price is low compared with the company's accounting value, but that cheapness is not supported by profits.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer